Skip to main content
. 2022 Sep 28;12(10):1601. doi: 10.3390/jpm12101601

Figure 2.

Figure 2

Summaries the utility of biomarkers in drug development in ALS spans from preclinical models, with translational biomarkers, to real-life studies.